Radiosensitization of non-small cell lung cancer by kaempferol

Oncology Reports

Volumn 34, Issue 5, 2015, Pages 2351-2356

  Yao, Chun Hsu ^d,f   Kuo, Wei Ting ^a   Tsai, Yuan Chung ^b   Wu, His Chin ^c   Ho, Yung Jen ^d   Chen, Yueh Sheng ^d   Yao, Chen Han ^e  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Graduate Institute of Clinical Medical Science   (Taiwan)

^c Fu Jen Catholic Uiversity   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e Viator Catholic High School   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Kaempferol; Lung cancer; Radiation; Radiosensitizer

Indexed keywords

KAEMPFEROL; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; KAEMPFEROL DERIVATIVE; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL GROWTH; CELL KILLING; CELL VIABILITY; CLONOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; G2 PHASE CELL CYCLE CHECKPOINT; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; RADIATION RESPONSE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; KAEMPFEROLS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE, INBRED BALB C; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941979069     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4204     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med 359: 1367-1380, 2008.
4. Pisters KM, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis PM, et al; Cancer Care Ontario; American Society of Clinical Oncology: Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 25: 5506-5518, 2007.
5. Crinò L, Weder W, van Meerbeeck J and Felip E; ESMO Guidelines Working Group: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (Suppl 5): v103-v115, 2010.
6. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N and Ariyoshi Y: Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699, 1999.
7. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, et al; American Society of Clinical Oncology: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 22: 330-353, 2004.
8. Eberhardt W, Pöttgen C and Stuschke M: Chemoradiation paradigm for the treatment of lung cancer. Nat Clin Pract Oncol 3: 188-199, 2006.
9. Wardman P: Chemical radiosensitizers for use in radiotherapy. Clin Oncol (R Coll Radiol) 19: 397-417, 2007.
10. Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, McKenna WG, Birnbaum MJ and Bernhard EJ: Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65: 7902-7910, 2005.
11. Reardon DB, Contessa JN, Mikkelsen RB, Valerie K, Amir C, Dent P and Schmidt-Ullrich RK: Dominant negative EGFRCD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 18: 4756-4766, 1999.
12. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, et al: Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 72: 239-248, 2012.
13. Wang T, Hu YC, Dong S, Fan M, Tamae D, Ozeki M, Gao Q, Gius D and Li JJ: Co-activation of ERK, NF-kappaB, and GADD45beta in response to ionizing radiation. J Biol Chem 280: 12593-12601, 2005.
14. Kuo WT, Ho YJ, Kuo SM, Lin FH, Tsai FJ, Chen YS, Dong GC and Yao CH: Induction of the mitochondria apoptosis pathway by phytohemagglutinin erythroagglutinating in human lung cancer cells. Ann Surg Oncol 18: 848-856, 2011.
15. Miean KH and Mohamed S: Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem 49: 3106-3112, 2001.
16. Agarwal OP and Nagaratnam A: Radioprotective property of flavonoids in mice. Toxicon 19: 201-204, 1981.
17. Park JS, Rho HS, Kim DH and Chang IS: Enzymatic preparation of kaempferol from green tea seed and its antioxidant activity. J Agric Food Chem 54: 2951-2956, 2006.
18. Li W, Du B, Wang T, Wang S and Zhang J: Kaempferol induces apoptosis in human HCT116 colon cancer cells via the Ataxia-Telangiectasia Mutated-p53 pathway with the involvement of p53 upregulated modulator of apoptosis. Chem Biol Interact 177: 121-127, 2009.
19. Luo H, Rankin GO, Liu L, Daddysman MK, Jiang BH and Chen YC: Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells. Nutr Cancer 61: 554-563, 2009.
20. DuPont MS, Day AJ, Bennett RN, Mellon FA and Kroon PA: Absorption of kaempferol from endive, a source of kaempferol-3-glucuronide, in humans. Eur J Clin Nutr 58: 947-954, 2004.
21. Nöthlings U, Murphy SP, Wilkens LR, Henderson BE and Kolonel LN: Flavonols and pancreatic cancer risk: The multiethnic cohort study. Am J Epidemiol 166: 924-931, 2007.
22. Leung HW, Lin CJ, Hour MJ, Yang WH, Wang MY and Lee HZ: Kaempferol induces apoptosis in human lung non-small carcinoma cells accompanied by an induction of antioxidant enzymes. Food Chem Toxicol 45: 2005-2013, 2007.
23. Jeong JC, Kim MS, Kim TH and Kim YK: Kaempferol induces cell death through ERK and Akt-dependent down-regulation of XIAP and survivin in human glioma cells. Neurochem Res 34: 991-1001, 2009.
24. Ackland ML, van de Waarsenburg S and Jones R: Synergistic antiproliferative action of the flavonols quercetin and kaempferol in cultured human cancer cell lines. In Vivo 19: 69-76, 2005.
25. Kowalski J, Samojedny A, Paul M, Pietsz G and Wilczok T: Effect of kaempferol on the production and gene expression of monocyte chemoattractant protein-1 in J774.2 macrophages. Pharmacol Rep 57: 107-112, 2005.
26. Sotibrán AN, Ordaz-Téllez MG and Rodríguez-Arnaiz R: Flavonoids and oxidative stress in Drosophila melanogaster. Mutat Res 726: 60-65, 2011.
27. Moon SS, Rahman MA, Manir MM and Jamal Ahamed VS: Kaempferol glycosides and cardenolide glycosides, cytotoxic constituents from the seeds of Draba nemorosa (Brassicaceae). Arch Pharm Res 33: 1169-1173, 2010.
28. Xu X, Xie H, Hao J, Jiang Y and Wei X: Flavonoid glycosides from the seeds of Litchi chinensis. J Agric Food Chem 59: 1205-1209, 2011.
29. Cory S and Adams JM: The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656, 2002.
30. Fletcher JI, Meusburger S, Hawkins CJ, Riglar DT, Lee EF, Fairlie WD, Huang DC and Adams JM: Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proc Natl Acad Sci USA 105: 18081-18087, 2008.
31. Nguyen TT, Tran E, Ong CK, Lee SK, Do PT, Huynh TT, Nguyen TH, Lee JJ, Tan Y, Ong CS, et al: Kaempferol-induced growth inhibition and apoptosis in A549 lung cancer cells is mediated by activation of MEK-MAPK. J Cell Physiol 197: 110-121, 2003.
32. Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 59: 928-942, 2004.
33. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319, 2006.